Are adverse events (AEs) during first-line FOLFIRINOX (FFX) more frequent in real-world (RW) patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who do not proceed to second-line therapy ...
Landscape of functional DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Carcinoid tumors are often described as “quiet cancers.” They grow slowly, may appear in unexpected parts of the body, and can cause subtle or easily overlooked symptoms. Because of this, many ...
Instructor in surgery, New York University College of Medicine; adjunct surgeon, Beth Israel Hospital. Edward A. Horowitz, M.D. Associate gynecologist, Beth Israel Hospital. Select the format you want ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results